Ultragenyx Pharmaceutical (RARE) Profit After Tax (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Profit After Tax data on file, last reported at -$185.0 million in Q1 2026.

• Profit After Tax for Q1 2026 came in at -$185.0 million, down 22.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$608.9 million (down 10.85% YoY), and the FY2025 annual result was -$575.0 million, down 1.05% from the prior year.
• Profit After Tax slipped to -$185.0 million in Q1 2026 per RARE's latest filing, from -$128.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$115.0 million in Q2 2025 and troughed at -$245.1 million in Q3 2022.
• A 5-year average of -$155.5 million and a median of -$152.3 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax slumped 235.77% in 2022, then jumped 34.87% in 2023.
• A 5-year view of Profit After Tax shows it stood at -$151.8 million in 2022, then grew by 18.63% to -$123.6 million in 2023, then decreased by 7.81% to -$133.2 million in 2024, then gained by 3.49% to -$128.6 million in 2025, then tumbled by 43.91% to -$185.0 million in 2026.
• Business Quant data shows RARE's Profit After Tax at -$185.0 million in Q1 2026, -$128.6 million in Q4 2025, and -$180.4 million in Q3 2025.